DexCom, Inc. (DXCM) Depreciation & Amortization
The d&a for DexCom, Inc. (DXCM) is $251.80 Million with a year-over-year change of +15.66%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
DXCM D&A Chart
Current D&A
$251.80M
$251.80 Million
Year-over-Year Change
+15.66%
vs. $217.70M prior year
Historical Data
26
Years of data available
Annual D&A History
| Year | D&A | YoY Change | % Change |
|---|---|---|---|
| 2025 | $251.80M | +$34.10M | +15.66% |
| 2024 | $217.70M | +$31.70M | +17.04% |
| 2023 | $186.00M | +$30.10M | +19.31% |
| 2022 | $155.90M | +$54.00M | +52.99% |
| 2021 | $101.90M | +$34.80M | +51.86% |
| 2020 | $67.10M | +$18.40M | +37.78% |
| 2019 | $48.70M | +$19.60M | +67.35% |
| 2018 | $29.10M | +$13.00M | +80.75% |
| 2017 | $16.10M | +$1.10M | +7.33% |
| 2016 | $15.00M | +$4.20M | +38.89% |
| 2015 | $10.80M | +$2.40M | +28.57% |
| 2014 | $8.40M | +$1.40M | +20.00% |
| 2013 | $7.00M | +$400,000 | +6.06% |
| 2012 | $6.60M | +$2.84M | +75.58% |
| 2011 | $3.76M | +$1.32M | +54.25% |
| 2010 | $2.44M | +$64,000 | +2.70% |
| 2009 | $2.37M | $-1.21M | -33.75% |
| 2008 | $3.58M | +$250,000 | +7.50% |
| 2007 | $3.33M | +$634,088 | +23.50% |
| 2006 | $2.70M | +$1.63M | +153.32% |
| 2005 | $1.07M | +$129,513 | +13.84% |
| 2004 | $935,494 | +$581,944 | +164.60% |
| 2003 | $353,550 | +$353,550 | — |
| 2002 | $0 | +$0 | — |
| 2001 | $0 | +$0 | — |
| 2000 | $0 | — | — |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach